CRABP2 and ovarian serous adenocarcinoma: CRABP2 promotes epithelial mesenchymal transition (EMT) in serous ovarian cancer by upregulating the expression of enhancer of zeste homolog 2 and promoting the methylation of tripartite motif containing 16 (TRIM16) [43].